Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,728JPY
20 Jul 2018
Change (% chg)

¥-6 (-0.13%)
Prev Close
¥4,734
Open
¥4,759
Day's High
¥4,764
Day's Low
¥4,691
Volume
3,238,600
Avg. Vol
5,208,600
52-wk High
¥6,693
52-wk Low
¥4,203

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  4502.T Industry Sector
P/E (TTM): 30.36 30.93 32.76
EPS (TTM): 203.74 -- --
ROI: 5.07 15.07 14.61
ROE: 8.38 16.60 16.34

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc , taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

10 Jul 2018

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

10 Jul 2018

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

10 Jul 2018

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

10 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise 60 billion yen: Nikkei

TOKYO Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc , the Nikkei business daily reported on Thursday.

05 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise Y60 bln - Nikkei

TOKYO, July 5 Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc, the Nikkei business daily reported on Thursday.

05 Jul 2018

Q2 slowdown hits Asian lending

Hong Kong, June 29 (TRLPC) - Syndicated lending in Asia Pacific, excluding Japan, showed a steep 31% year-on-year decline to US$94.17bn in the second quarter, dragging first-half borrowing volumes down 9.2% to US$211.60bn, according to Thomson Reuters LPC data.

29 Jun 2018

Return of mega-deals helps European M&A double

LONDON A resurgence in mega-deals has led to a doubling of mergers and acquisitions activity in Europe so far this year, raising questions among bankers and lawyers about when the pace of blockbuster transactions will start to fade.

29 Jun 2018

Deals of the day-Mergers and acquisitions

June 28 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

28 Jun 2018

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc , failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

28 Jun 2018

Earnings vs. Estimates